MB-105, a CD5-targeted CAR-T cell therapy, has received FDA regenerative medicine advanced therapy designation for relapsed/refractory CD5-positive T-cell lymphoma. The designation aims to expedite ...
(Bloomberg) -- The US Food and Drug Administration is rolling out a new program to speed up drug reviews by emphasizing clearer, more frequent communication with companies, aided by a surge of new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results